Emcure buys out Gennova in ₹2,318.7M deal for full control
What's the deal? Emcure PharmaceuticalsDealroom has a profile for this one. Try Dealroom → is acquiring the remaining 12.05% stake in Gennova Biopharmaceuticals for ₹2,318.7 million in cash, taking its holding from 87.95% to 100%. The purchase of 663,865 equity shares from individual shareholders will make Gennova a wholly-owned subsidiary.
Why now? Gennova has already been an Emcure subsidiary, and both are classified as related parties. Emcure expects to close the deal, structured across one or more tranches, on or before July 31, 2026.
What's the endgame? Gennova develops, manufactures, and markets biotechnology-based products from its base in Pune, Maharashtra. Full ownership hands Emcure complete control over the biotech unit, which it first backed under the name Emcure Dragon Biotech Limited before its 2006 rebrand.
By the numbers: Gennova posted turnover of ₹4,917.42 million for the year ended March 31, 2026, up from ₹4,299.46 million a year earlier and ₹4,220.82 million in FY24. Profit after tax was ₹54.25 million.
What could go wrong? The deal awaits completion, and Emcure shares slipped 1.40% to ₹1,793.3 in post-market trading on 87,267 shares. Consolidating a low-margin biotech unit — profit was a thin slice of turnover — adds full financial exposure to Emcure's books.
The signal: Buying out minority holders to fold a partly-owned biotech arm into a wholly-owned subsidiary lets Emcure tighten control over its biotechnology pipeline. It is a familiar consolidation play among pharmaceutical groups seeking cleaner ownership of R&D-heavy assets.
Read more: investoomarket.com
